Market Cap | 4.97M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -378k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -25.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -34.00% |
Dividend | N/A | Price/Book | 1.35 | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | - | Quick Ratio | 10.49 | Shares Outstanding | 5.45M | 52W Low Chg | 8.00% |
Insider Own | 5.30% | ROA | -13.78% | Shares Float | 486.31M | Beta | 0.94 |
Inst Own | 2.09% | ROE | -13.07% | Shares Shorted/Prior | 9.70K/10.36K | Price | 0.81 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 14,548 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 950 | Change | 1.13% |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
HC Wainwright & Co. | Buy | May 8, 15 |